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Abstract
Background: Bone grafts from bone banks might be mixed with bisphosphonates to inhibit the osteoclastic
response. This inhibition prevents the osteoclasts to resorb the allograft bone before new bone has been formed
by the osteoblasts, which might prevent instability. Since bisphosphonates may not only inhibit osteoclasts, but
also osteoblasts and thus bone formation, we studied different bisphosphonate concentrations combined with
allograft bone. We investigated whether locally applied alendronate has an optimum dose with respect to bone
resorption and formation. Further, we questioned whether the addition of demineralized bone matrix (DBM),
would stimulate bone formation. Finally, we studied the effect of high levels of antibiotics on bone allograft
healing, since mixing allograft bone with antibiotics might reduce the infection risk.
Methods: 25 goats received eight bone conduction chambers in the cortical bone of the proximal medial tibia.
Five concentrations of alendronate (0, 0.5 mg/mL, 1 mg/mL, 2 mg/mL, and 10 mg/mL) were tested in combination
with allograft bone and supplemented with cefazolin (200 μg/mL). Allograft not supplemented with alendronate
and cefazolin served as control. In addition, allograft mixed with demineralized bone matrix, with and without
alendronate, was tested. After 12 weeks, graft bone area and new bone area were determined with manual point
counting.
Results: Graft resorption decreased significantly (p < 0.001) with increasing alendronate concentration. The area of
new bone in the 1 mg/mL alendronate group was significantly (p = 0.002) higher when compared to the 10 mg/
mL group. No differences could be observed between the group without alendronate, but with demineralized
bone, and the control groups.
Conclusions: A dose-response relationship for local application of alendronate has been shown in this study. Most
new bone was present at 1 mg/mL alendronate. Local application of cefazolin had no effect on bone remodelling.
Background
Different types of bone grafts from bone banks are
widely used for the restoration of bone defects in clini-
cal practice with satisfying clinical outcomes [1,2]. In
addition, allograft bone bank chips are used during bone
impaction grafting, a well-accepted and clinical success-
ful procedure for the restoration of bone stock loss
around loose implants [3-5]. This procedure is hence
applied during revision arthroplasty. A possible problem
associated with the use of bone grafts in loaded
conditions, like in revisions, is a too fast resorption of
graft material. Accelerated bone graft resorption before
the formation of new bone may cause loss of stability,
ultimately resulting in failure of the revised hip or knee
implant [6-8].
Bisphosphonates might reduce bone graft resorption
by inhibition of the osteoclasts [9]. Bisphosphonates
have a high affinity for Ca2+, and therefore are targeted
to areas of high bone turnover and adhere closely and
selectively to sites of active bone remodelling. Osteo-
clasts trying to resorb the bone, release the bisphospho-
nates from the bone mineral. Bisphosphonates become
internalized in the osteoclast, resulting in apoptosis of
the osteoclast [10].
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Although bisphosphonates efficiently suppress bone
resorption by apotosis of osteoclasts, systemic treatment
will only reach the revascularized parts of the bone graft
and the concentration of bisphosphonates in regions of
the skeleton with low blood perfusion, for example the
femoral neck, will be very low [11-13]. Therefore, in sev-
eral studies a bisphosphonate solution was administered
locally, with varying results [9,12,14-17]. In these stu-
dies, it was hypothesized that local application of
bisphosphonates would decrease resorption after
implantation of a new prosthesis. This might prevent
mechanical instability and therefore provide better sup-
port during the early process of healing after the opera-
tion. This way, bone resorption and bone formation
might be more balanced. Baas et al. [16] were not able
to change this balance between bone formation and
bone resorption. The bisphosphonate virtually blocked
bone metabolism in their study. In addition, Jakobsen et
al. [15] found a substantially decreased biomechanical
implant fixation when the impacted morselized allograft
had been soaked in bisphosphonate. On the contrary, it
has been shown that local bisphosphonate treatment
can protect the graft from resorption during the early
postoperative period [9,12]. It has been suggested that
bisphosphonates not only inhibit osteoclastic activity,
but also might have a decreased anabolic or even a toxic
effect on osteoblasts; a too high concentration of the
unbound bisphosphonate may not only inhibit the
osteoclasts but also the osteoblasts, and thus reduce
new bone formation [18]. It is therefore important that
the concentration of unbound free bisphosphonate is
below the level in which osteoblasts are inhibited
[9,15,16,19,20].
The chance of failure of a reconstruction is greatest
immediately after surgery, when the graft bone has not
been incorporated yet. This critical period after recon-
struction with bone impaction grafting might be shor-
tened when demineralized bone matrix (DBM) is used.
DBM is a product of processed allograft bone and con-
tains collagen, proteins and growth factors [21]. Demi-
neralization of bone theoretically facilitates the release
of growth factors which could increase the bioactivity of
the graft and positively influence new bone formation
and thus the amount of new bone [22,23] which might
be of importance during the early critical period.
Another devastating complication following joint
replacement surgery is infection. Systemic administered
antibiotics are widely used to prevent and cure infection,
however these antibiotics cannot easily reach the
infected bone in an avascular area [24]. In addition, for-
mation of a biofilm on the surface of the implant makes
the systemic administered antibiotics less effective [25].
A solution to achieve high local antibiotic concentra-
tions is to impregnate bone allograft chips with
antibiotics. Several studies have shown that morselized
bone can act as a carrier for antibiotics [26-32]. These
studies show, both in vitro as in vivo, that bone grafts
impregnated with antibiotics can be used as a prophy-
laxis against infections. However, the effectiveness of
bone allograft healing in the presence of high levels of
antibiotics has yet to be determined.
In this study we combined the local application of
bisphosphonate, DBM and antibiotics with allograft
bone chips in a bone chamber. The purpose of this
study was to investigate the dose-response relation of
alendronate-impregnated allograft with respect to the
amount of graft bone and the amount of new bone or
total bone after 12 weeks. We investigated whether
locally applied alendronate has an optimum dose with
respect to bone resorption and net bone formation. The
second question of this study was whether the addition
of DBM to bone chips impregnated with bisphosphonate
would stimulate bone formation. Finally, we investigated
whether the local application of antibiotics has an effect
on bone remodelling.
Methods
Study design
25 mature Dutch female goats (Capra Hircus Sana,
range 49-70 kg) bilaterally received four bone chambers
in the cortical bone of the proximal medial tibia. The
side and position of implantation of the 8 chambers
were alternated with a random start. The bone conduc-
tion chamber consists of a titanium screw with a cylind-
rical interior space [33]. It is made up of two threaded
half-cylinders held together by a hexagonal closed screw
cap. The interior of the chamber has a diameter of 2
mm and a length of 7.5 mm. There are two openings at
the end of the chamber to enable bone ingrowth. The
threaded end of the implant is screwed into the tibia of
the goat, so that the ingrowth openings are in direct
contact with the endosteal transition from marrow into
bone. Originally developed as a rat model, the bone con-
duction chamber was adjusted for use in goats [34].
Since the tibial cortex in rats is thinner than in goats, a
1-mm thick plate was inserted into the cap to lower the
ingrowth openings through the cortex.
Five concentrations of bisphosphonates (0, 0.5, 1, 2,
and 10 mg/mL alendronate, Fosamax, MSD) were com-
bined with allograft bone supplemented with antibiotics
(200 μg/mL cefazolin) (ALL + AB, ALL + AB + 0.5BIS,
ALL + AB + 1BIS, ALL + AB + 2BIS, and ALL + AB +
10BIS). Allograft not supplemented with alendronate
and cefazolin served as control (ALL). In addition, allo-
graft mixed with DBM with alendronate (1 mg/mL)
(ALL + DBM + BIS) and without alendronate (ALL +
DBM) were tested (Table 1). The observation time was
12 weeks.
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Our sample size calculation was based on the results
of a study of Aspenberg and Astrand [9]. The minimal
relevant difference of bone formation was set to 27%
and based on this study, we assumed the standard devia-
tion on the relative change to be 8%. Two sided a and b
were set to be 5% and 10% respectively.
All procedures were approved by our institutional
Animal Ethics Committee.
Bone graft preparation
Cancellous bone graft was obtained under sterile condi-
tions from the sternum of three donor goats. Bone
grafts were morselized into chips of approximately 1-2
mm, pooled and rinsed with saline with pulse lavage
(Pulsavac® Plus, Zimmer, Swindon, UK) for two minutes
to remove blood and marrow.
Bone chips were impregnated with 5 ml alendronate
(Fosamax, MSD) and/or 5 ml cefazolin solutions for 10
min, then rinsed 3 times in 5 ml saline at room tem-
perature for 3 min. Rinsing was done to remove
unbound and excessive alendronate and/or cefazolin.
Alendronate solution was prepared by dissolving one 10
mg tablet in 5 ml of saline for 1 h and then passing it
through a sterile Millipore filter with a pore size of 0.2
mm. To obtain the different concentrations, this alen-
dronate solution was diluted.
The concentration of cefazolin was 200 μg/mL. This
concentration was based on an earlier performed in
vitro study, in which the amount of antibiotics on the
allograft bone was determined after impregnation of the
bone chips with cefazolin [35]. The amount of cefazolin
present on the bone chips after rinsing 3 times with sal-
ine was determined and appeared to be well above the
Minimal Inhibitory Concentration (MIC) for S. Epider-
midis and about 1/3 of the amount of cefazolin present
on the bone chips without rinsing. Additional data
(unpublished) showed that impacting the bone graft
chips after impregnation with cefazolin, did not have an
effect on the amount of cefazolin present on the bone
chips, compared to not impacting the bone chips. Tests
were performed according to the protocol as described
earlier [35]. According to Edin et al. [36], local levels of
cefazolin of 200 μg/mL decrease cell replication, but
local levels of 100 μg/mL do not affect the replication of
osteoblasts. Freeze-dried DBM (size 80-800 μm) was
prepared at DIZG (Deutsches Institut fur Zell- und
Gewebeersatz, Berlin, Germany) from the cortical bone
of two donor goat femora under sterile conditions.
DBM was rehydrated and mixed with the cancellous
bone graft chips in a 50/50 volume ratio.
Impaction was performed by gradually filling the cham-
bers with the allograft preparations. A piston slightly smal-
ler in diameter (1.9 mm) was used for impaction. The
piston was guided by low friction bearings, strictly limiting
it to vertical movement. During impaction, the chamber
was clamped into a cylindrical holder. A constant force of
40 N was kept on the free end of the piston for two min-
utes. During this time, fluid could escape between the pis-
ton and the wall of the bone chamber and the ingrowth
openings. The pressure applied was calculated to be 25
MPa. With this method of impaction, the mean volume
fraction of graft bone in the bone chamber rises from
about 35% in unimpacted grafts to about 65% in impacted
ones [37]. After impaction, the screw cap was placed on
the cylinder and the bone conduction chamber was stored
at -80°C until use. The bone chambers were thawed at
room temperature before implantation.
Surgical procedure
Goats were anesthetized with medetomidine (5 μg/kg)
and propofol (3-5 mg/kg), intubated, and maintained
using isoflurane and oxygen in a semiclosed ventilation
system. The goats were placed in supine position. The
lower legs were shaved, washed, iodized and covered
with sterile cloths. A longitudinal incision was made in
the skin and fascia over the medial side of the proximal
tibia. The cortical bone was explored and a hole was
drilled through the medial cortex at approximately 4 cm
from the joint cleft using a 3.2-mm drill. The hole was
tapped and bone debris from drilling was removed. The
bone conduction chamber was screwed in manually.
The other three bone conduction chambers were placed
10 mm from each other. This was repeated for the
other side. The skin was sutured in two layers.
After the operation, goats received injections of anti-
biotics (15 mg/kg) (ampicilline) and analgetics (1 mg/kg)
(flunixin). All animals were allowed unrestricted move-
ment in their cages and had free access to water and food
after the operation. After 12 weeks, the goats were killed
with an overdose of sodium pentobarbital (0.5 mL/kg).
Histological and histomorphometric evaluation
Tibiae were removed and the bone conduction chambers
with surrounding cortex were fixed in 4% buffered
Table 1 Overview of experimental design
Group Alendronate
(mg/mL)
Cefazolin (μg/mL) DBM
ALL - - -
ALL + AB - 200 -
ALL + AB + 0.5BIS 0.5 200 -
ALL + AB + BIS 1 200 -
ALL + AB + 2BIS 2 200 -
ALL + AB + 10BIS 10 200 -
ALL + DBM - - +
ALL + DBM + BIS 1 - +
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formalin. After 1 day the contents were removed from
the bone chambers and fixed additionally for at least 5
days. After dehydration in ethanol and plastic embedding
(polymethylmethacrylate), non-decalcified 7-mm thick
serial sections were made along the longitudinal axis of
the specimen. Sections were stained with hematoxylin
and eosin and Goldner-Masson for routine histological
analysis. Histomorphometric quantitative analysis was
done blindly using digitalized pictures of the sections.
Three central sections in each specimen were studied,
each 250 μm apart. Manual point counting was per-
formed using custom-made stereological software. The
total number of points, points covering bone in general
and points covering new living bone were counted. Graft
bone was identified by its highly organized lamellas and
oval cell lacunae without nucleic material, whereas newly
formed bone was less organized and contained nucleic
material. On average, 100 point were counted in each
section, resulting in 300 points per specimen All sections
were blinded and evaluated in random order.
Statistics
Results were analysed non-parametrically, therefore
Friedman’s repeated measurements ANOVA on ranks
with a Wilcoxon signed ranks test with a Bonferroni
adjustment was used to differentiate between groups.
SPSS software version 18.0 was used. Statistical signifi-
cance was set at p < 0.05.
Results
All goats were able to stand normally on their hind legs
1 to 2 days after surgery. There were no signs of inflam-
mation, skin ulceration or wound healing problems.
Three goats died during the 12 week period, of reasons
not related to surgery. These goats were not excluded
from analysis, since they died a few days before sacrifi-
cation. 8 bone chambers were loose and excluded, they
originated from the control group (1), control with cefa-
zolin group (2), 0.5 mg/mL alendronate group (1), 2
mg/mL alendronate group (1), 10 mg/mL alendronate
group (2) and of the DBM group (1).
Histology
In general, bone chambers were surrounded by a layer
of callus and covered with fibrous tissue. The graft bone
in the control group was almost entirely resorbed
(Figure 1A), while in the alendronate groups the bone
chambers were full with graft bone as well as new bone
(Figure 1B). A homogeneous distribution of DBM was
present in non-resorbed areas within the bone chamber
(Figure 1C). Two different incorporation patterns were
found in the ALL, ALL + AB, ALL + DBM groups on
the one hand (Figure 1A) and all the other groups
where BIS was added on the other hand. (Figure 1B).
In all groups without BIS (ALL, ALL + AB, ALL +
DBM) similar patterns of resorption and new bone for-
mation were present. All bone graft (including DBM if
present) was resorbed or a resorption front could be
found at the interface with allograft remnants
(Figure 1D). This front, if still present, consisted of
numerous lymphocytic cells that had penetrated into the
graft (Figure 1D). Numerous osteoclasts in a blood ves-
sel rich area resorbed all allograft and DBM if present
(Figure 1D). No obvious differences were found between
the activity of osteoclasts on allograft bone or DBM
(Figure 1D, F). Between the resorption front and the
area with new bone in almost all chambers a thick
fibrous interface was present containing fibroblasts and
some macrophages (Figure 1A). New bone formation
was mainly found at the direct vicinity of the ingrowth
holes (Figure 1A, H). The newly formed bone contained
no or scarce remnants of ALL or DBM. In most cham-
bers a strong remodeling activity was still present as is
visualized by the red non-calcified zones in the Goldner
stained sections (Figure 1J).
In all groups with BIS the delineation of the resorp-
tion front was less clear. Lower numbers of osteoclasts
were present on the bone graft particles (Figure 1E)
compared to all groups without BIS. Histologically no
clear differences could be found in the number of osteo-
clasts in the different BIS concentration groups. After
the passage of the revascularization front through the
bone graft, the non-resorbed ALL and/or DBM were
surrounded by fibrous tissue (Figure 1E). Newly formed
bone was present in a much larger area compared to all
groups without BIS (Figure 1B). Bone was formed on
the remnants of ALL or DBM (Figure 1G, J). No clear
differences were found between the resorption of ALL
and DBM. In the area with new bone most allograft
bone was mineralized. In the Goldner stained sections
some focal areas with non-mineralized DBM were pre-
sent, but round green spots in the DBM particles sug-
gest that they underwent a process of mineralization
after incorporation into new bone (Figure 1J).
Histomorphometry
Cefazolin
No significant differences could be observed between
the cefazolin group (ALL + AB) and the control group
(ALL), for total bone volume, graft bone volume or new
bone volume (Tables 2, and 3, Figure 2 and 3)
Alendronate
An alendronate dose-dependent difference in the amount
of graft bone was found (Table 2, Figure 2). Graft resorp-
tion decreased with increasing alendronate concentration.
All groups treated with alendronate differed significantly (p
< 0.001) when compared to the volume fraction of allograft
bone of the control group. These significant differences for
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volume fraction of allograft bone were also observed
between the four alendronate-groups; with increasing
amounts of alendronate, a decrease in graft resorption was
found, which were all significantly different.
Bone formation in the four alendronate groups was
significantly different when compared to the control
group (p < 0.001) (Table 3, Figure 3).
When bone formation in the 1 mg/ml (ALL + AB +
BIS) was compared to bone formation in the 10 mg/ml
(ALL + AB + 10BIS) group, the volume fraction of new
bone was significantly lower in the highest alendronate
group (Tables 2, and 3).
Demineralized bone matrix
When the group with DMB (ALL + DBM) was com-
pared to the control group, no differences could be
observed (Tables 2, and 3).
Discussion
The purpose of this study was to investigate the dose-
response relationship of alendronate-impregnated allograft
with respect to the amount of graft bone and the amount
of new bone or total bone after 12 weeks in a goat bone
chamber model. Also, the effects of adding DBM and the
local application of antibiotics (cefazolin) were tested.
Figure 1 Histological results. A. Typical example of ALL + DBM group. Notice large area of fibrous tissue (FT) between graft remnants (right)
and new bone (NB). B. Typical example of BIS + DBM group. Bone chamber is fully filled with a mixture of graft remnants, DBM and new bone.
C. Non incorporated mixture of bone graft (BG) and demineralized bone (DBM) of ALL + DBM + BIS group. D. The incorporation front in a
chamber with ALL. Arrows point at osteoclasts. E. Fibrous tissue surrounding bone grafts. ALL + AB + 2BIS group. F. Osteoclasts on DBM bone
particle. ALL + DBM group. G. Enlargement of bone in ALL + AB + 2BIS group. Notice mixture of new bone (NB) with osteocytes and bone graft
(BG). H. New bone formed in ALL + DBM group. J. Ossification (arrows) of BIS particles in bone chamber of ALL + DBM + BIS group. Bars are 1
mm (A, B), 500 μ (H), 250 μ (C, D, E, J) or 100 μM (F, G).
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We showed a dose-response relation for local applica-
tion of alendronate with respect to the amount of new
bone as well as the amount of graft bone present in the
bone chamber after 12 weeks. Decreased implant fixa-
tion has been observed with higher doses of bisphopho-
nates (by blocking bone metabolism completely) [16].
Therefore, an optimum dose regarding bone resorption
is essential, since it yields a positive balance between
allograft resorption and the net amount of newly formed
bone which results in improved fixation.
Our results show that with increasing alendronate con-
centration, graft resorption decreased and the amount of
necrotic graft bone, left after 12 weeks, increases. This is in
accordance with the study of Jakobsen et al. [20], in which
another bisphosphonate, zoledronate, was used. They also
studied different bisphosphonate concentrations, however
their volume fractions of allograft bone were much higher
compared to our study. Our volume fractions of allograft
bone were 10.9% (± 8.8) for the lowest alendronate group
to 32.8% (± 8.7) for the highest alendronate group, while in
the study of Jakobsen, graft bone volume fractions started
with mean values above 30%. These differences in results
might also be explained by the rinsing method used (3 min
vs 10 min) or the fact that Jakobsen had a mechanically
loaded situation compared to our unloaded situation.
Agholme et al. [17] also used alendronate locally (2 mg/
mL) and found volume fractions of allograft bone com-
pared to ours. In contrast to our study, they did not find
Table 2 Overview of statistical results (graft bone)
Group ALL ALL + AB ALL + AB ALL + AB ALL + AB ALL + AB ALL+ ALL+
+0.5BIS +BIS +2BIS +10BIS DBM DBM + BIS
ALL - - - - - - - -
ALL + AB 0.674 - - - - - - -
ALL + AB+ < 0.001* < 0.001* - - - - - -
0.5BIS
ALL + AB+ < 0.001* < 0.001* < 0.001* - - - - -
BIS
ALL + AB+ < 0.001* < 0.001* < 0.001* 0.001* - - - -
2BIS
ALL + AB+ < 0.001* < 0.001* < 0.001* < 0.001* 0.003 - - -
10BIS
ALL + DBM 0.003 0.003 < 0.001* < 0.001* < 0.001* < 0.001* - -
ALL+ 0.01 < 0.001* 0.000* 0.001* 0.003 0.36 < 0.001* -
DBM + BIS
*significant: p < 0.0018 (Bonferroni adjustment due to 28 different comparisons)
Table 3 Overview of statistical results (new bone)
Group ALL ALL + AB ALL + AB ALL + AB ALL + AB ALL + AB ALL+ ALL+
+0.5BIS +BIS +2BIS +10BIS DBM DBM + BIS
ALL - - - - - - - -
ALL + AB 0.07 - - - - - - -
ALL + AB+ < 0.001* 0.06 - - - - - -
0.5BIS
ALL + AB+ < 0.001* < 0.001* < 0.001* - - - - -
BIS
ALL + AB+ < 0.001* < 0.001* 0.007 0.219 - - - -
2BIS
ALL + AB+ < 0.001* 0.285 0.049 0.002 0.018 - - -
10BIS
ALL + DBM 0.344 0.181 0.001* < 0.001* < 0.001* < 0.001* - -
ALL+ < 0.001* 0.11 0.375 < 0.001* 0.043 0.331 < 0.001* -
DBM + BIS
*significant: p < 0.0018 (Bonferroni adjustment due to 28 different comparisons)
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any differences between the amount of new bone between
a regular dose (with rinsing after impregnation) of bispho-
sphonate and an overdose amount (without rinsing the
graft after impregnation). The volume fractions of new
bone were comparable to the mean volume fractions of the
4 different doses in our study, although we did find differ-
ences between the doses. They stated that their results may
be explained by the four-week study period in their experi-
ments compared to the 6 weeks period in other studies
(and thus the 12 week period in our study), that there was
not enough time to fully resorb all allograft bone behind
the bone ingrowth frontier.
Zoledronate is used in several studies for local applica-
tion of bisphosphonate and is a more potent bispho-
sphonate compared to alendronate [38]. Differences in
graft volume fractions between local application of alen-
dronate and zoledronate might be explained by this.
Alendronate was chosen in this study as bisphosphonate
since it has been used as osteoporosis prophylaxis treat-
ment for almost two decades [39].
The amount of new bone in our experiment showed
an optimum at a dose of 1 mg/mL alendronate. The
amount of new bone was significantly higher compared
to control and also when compared to lower and higher
alendronate concentrations.
A possible explanation for the difference in newly
formed bone between control and BIS groups is that in
the control groups the newly formed bone is rapidly remo-
deled by osteoclasts. This yields a net low amount of new
bone, which is entirely the result of osteoclastic activity
and might explain the differences observed. Jakobsen et al.
stated that this effect could be explained by the preserving
effect of the bisphosphonate on the allograft, thereby
prolonging the osteoconductive effect [20].
An enhancing effect of application of bisphosphonate
locally on the amount of new bone has also been
observed in other studies [9,20,40,41] and are confirmed
by some in vitro studies [19,42-44]. However, it has not
been shown in vivo. The declination in the amount of
newly formed bone at the highest alendronate-group,
compared to lower alendronate groups, might be
explained by the toxicity of bisphosphonates on bone
tissue. At a high dose, bisphosphonates have been
shown to be toxic to osteoblasts [44,45]. Another expla-
nation might be the lack of space in the bone conduc-
tion chamber. The necrotic bone is not resorbed and
therefore, no room is left for the formation of new bone.
We chose cefazolin as antibiotic. This is the antibiotic
of first choice for orthopaedic surgery in The Nether-
lands. According to Edin et al. [36] local levels of cefa-
zolin 200 μg/mL decrease cell replication, but levels of
100 μg/mL do not affect the replication of osteoblasts.
The amount of cefazolin used in this study is well above
the MIC for S. Epidermidis, and did not affect bone
remodelling since no differences between the control
group and the allograft group impregnated with cefazo-
lin could be observed between for % graft bone volume
or % new bone volume. However, since our study was
powered to show differences, not equality, this result
should be interpreted cautiously. Taking into account
the half-life of cefazolin, it will stay above MIC - and be
effective- for at least 8 to 10 h which is enough for pro-
phylaxis. Cefazolin is completely eluted from the bone
chips after three days. No subinhibitory amount of the
drug is left behind which can induce resistancies and
therefore, cefazolin is an attractive choice for local pro-
phylaxis [29].
No effect of the addition of DMB to allograft bone has
been found in this study. In addition, histology shows
similar resorption characteristics for DBM and allograft
groups. The release of growth factors by osteoclastic
resorption of allograft bone or DBM is probably quite
similar. In addition, when combining DBM, alendronate
and allograft bone, no additional bone was formed. Our
results confirm several studies [46,47], although other
studies did find an enhancing effect of DBM on bone
formation [48,49]. Bae et al. [50] studied different DBM
Figure 2 Percentage graft bone of total volume for the 8
different groups.
Figure 3 Percentage new bone of total volume for the 8
different groups.
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products and found a higher variability in concentration
of bone morphogenic proteins among three different
lots of the same DBM than among the different DBM
products of different companies. Although our study
pooled DBM of two goats (and therefore pooled two dif-
ferent lots), we did not find any effect of the addition of
DBM to allograft bone.
Before implantation of the bone chamber we impacted
the allograft bone to simulate the clinical situation as
much as possible. However, caution should be taken
when extrapolating the results. This bone chamber
model in goats is un-loaded and therefore quite different
from the loaded conditions as in a clinical situation.
Also, no cement has been applied, as is done in a
cemented revision hip arthroplasty with bone impaction
grafting. In addition, a limitation of this study is the lack
of biomechanical testing that would determine whether
the groups treated with alendronate would be structu-
rally stronger than the control group.
Basic principle of bone impaction grafting is that
osteoclasts will resorb bone and osteoblasts will form
new woven bone. Micromotions during normal gait
cycles induce a rapid osteoclastic response. This too fast
bone resorption might lead to intial instability of the
implant, periprosthetic osteolysis and later implant
migration [6,7,11,51]. Local application of bisphospho-
nates has a clear influence on the osteoclastic activity,
but little is known of the effect on implant migration
and the occurrence of micromotions surrounding the
implant.
Conclusions
In conclusion, a dose-response relationship for local
application of alendronate with respect to graft resorp-
tion has been shown in this study. The area of new
bone in our experiment was optimal at 1 mg/mL alen-
dronate. At this concentration, the amount of new bone
was significantly higher compared to control and also
when compared to lower (0.5 mg/mL) and higher alen-
dronate concentrations (2 mg/mL). Local application of
cefazolin (200 μg/mL) had neither effect on bone forma-
tion nor on bone graft resorption. Therefore, cefazolin
at this concentration might be used as a prophylaxis
against infection. The addition of DBM did not enlarge
the new bone area.
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